Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
The awards were made on
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s lead candidate, FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency and is in development in Japan. Zogenix is preparing for a Type A meeting with the U.S. Food & Drug Administration to discuss resubmission of the company’s NDA. For more information, visit www.zogenix.com.
Senior Director, Corporate Communications
+1 (510) 788-8732 | email@example.com
Public Relations, Syneos Health
+1 (858) 449-9575 | firstname.lastname@example.org
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com
Source: Zogenix, Inc.